Snapshot · Johnson & Johnson (JNJ)
Sector: Healthcare / Drug Manufacturers - General
Data as of 2026-10-18T09:42:28.122Z
Fundamentals check
- Market cap
- $615.9B
- P/E (TTM)
- 38.7
- Gross margin
- 68.8%
- Net margin
- 16.2%
- ROE
- 19.7%
- R&D / revenue
- 16.2%
- Dividend yield
- 2.1%
- FCF yield
- 3.0%
Latest dividend: $1.34/share (ex-date 2026-11-24, quarterly)
Summary
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
How it makes money
Revenue mix, latest fiscal year
- Innovative Medicine64.1%
- MedTech35.9%
Recent Events
- 2026-10-17T06:15:00.000Zpositive
Johnson & Johnson Just Raised Its Sales Outlook Again. Here's Why the Dividend King Is Still a Buy.
可能与公司提升业绩展望相关，但市场反应仍含不确定性，恰逢股价波动。
Source: fool.com
- 2026-10-16T13:54:39.000Zneutral
Johnson & Johnson: 3 Key Takeaways for Long-Term Investors
可能与长期展望相关，但结论需结合后续数据验证，存在不确定性。
Source: fool.com
- 2026-10-14T13:06:01.000Zneutral
These Analysts Cut Their Forecasts On Johnson & Johnson After Q3 Results
可能与对后市预测调整相关，需结合公司实际表现与行业环境评估影响。
Source: benzinga.com
- 2026-10-14T09:21:23.000Zneutral
Stock of the Day: Is this the Bottom for Johnson & Johnson?
恰逢市场情绪波动，暂无法确认底部需观察后续走势，存在不确定性。
Source: benzinga.com
- 2026-10-13T15:52:34.000Znegative
Johnson & Johnson shares fall following earnings
可能与盈利增速放缓及股价波动相关，但仍需观察全年前景。
Source: youtube.com
- 2026-10-13T13:11:04.000Zmixed
Johnson & Johnson Q3 Earnings: Talc Resolution Offer Impacts Earnings, MedTech Slows Growth
可能与潜在诉讼和MedTech放缓有关，需关注后续解决方案与新产品推动。
Source: seekingalpha.com
- 2026-10-13T00:00:00.000Znegative
Price move: JNJ fell 5.7%
JNJ 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。
- 2026-08-18T00:00:00.000Zpositive
Price move: JNJ rose 3.3%
JNJ 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。
- 2026-07-30T00:00:00.000Znegative
Price move: JNJ fell 3.7%
JNJ 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。
Price & event timeline
Price & event timeline
Three months of price history with annotated events to help spot what may have driven a move.
筹码分布
资金流指标
以下为基于公开量价数据的技术指标估算，非真实主力资金流。
Analyst view
Wall Street ratings
Avg price target $286.5 from 14 analysts (last quarter)
Insider & Congress activity
聪明钱动向 · 近 90 天
内部人近 90 天整体偏卖出，国会议员披露整体偏卖出。
Open-market trades only; grants and exercises excluded
- 2026-09-02SellSchmid Timothy(officer: EVP, WW Chair, MedTech)22,527 shares
- 2026-08-17SellTaubert Jennifer L(officer: EVP, WWC. Innovative Medicine)15,000 shares
- 2026-08-13SellDuato Joaquin(director, officer: CEO and Chairman of the Board)102,315 shares
- 2026-08-13SellDuato Joaquin(director, officer: CEO and Chairman of the Board)20,976 shares
- 2026-08-06SellForminard Elizabeth(officer: EVP, Chief Legal Officer)6,574 shares
US Congress trading disclosures
- 2026-08-20John Boozman (AR)Sale (Partial)$1,001 - $15,000
Earnings Calendar
2027-01-20
EPS estimate: 2.93
Go deeper
订阅每日简报
每个交易日开盘/收盘后，中文市场简报直达邮箱。免费，随时退订。
本内容仅为信息整理，不构成任何投资建议。
Deep analysis
Deep analysis
Generate a full in-page analysis (business model, risks, scenarios). Not investment advice.